• Total revenue of NZ$44.9 million (14% growth)
• Myriad product revenue up 33% to NZ$19.7 million
• Normalised EBITDA profit of NZ$1.8 million (up from NZ$1.5 million loss)

Aroa Biosurgery Limited (ASX: ARX) has released its half-year results for the period ended 30 September 2025. The company reported total revenue of NZ$44.9 million, a 14% increase compared to H1 FY25. Myriad product revenue grew 33% to NZ$19.7 million, while OviTex/OviTex PRS revenue increased 4% to NZ$19.2 million. Product gross margin was 85%, compared to 87% in H1 FY25. The company generated a normalised EBITDA profit of NZ$1.8 million, compared to a NZ$1.5 million loss in H1 FY25. This improved EBITDA performance was driven by increased sales and improved management of trade debtors. The company reported positive net cash flow of NZ$1.5 million, ending H1 FY26 with a cash balance of NZ$23.4 million. AROA also announced that it has been relieved of its obligation to lodge quarterly 4C cash flow reports by the ASX, due to its consistent positive cash flow over the last 12 months.

AROA expects FY26 total revenue of NZ$92-100 million, representing 10-20% constant currency growth on FY25. The company also expects FY26 normalised EBITDA profit of NZ$5-8 million.

Looking ahead, AROA expects new clinical publications to further validate its AROA ECM technology and strengthen its commercial uptake.